rs104894434
Positions:
Variant summary
Our verdict is Likely pathogenic. Variant got 6 ACMG points: 6P and 0B. PM1PM2PP3_Moderate
The NM_000161.3(GCH1):āc.662T>Cā(p.Met221Thr) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000415 in 1,613,846 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Genomes: š 0.000020 ( 0 hom., cov: 33)
Exomes š: 0.000044 ( 0 hom. )
Consequence
GCH1
NM_000161.3 missense
NM_000161.3 missense
Scores
8
3
8
Clinical Significance
Conservation
PhyloP100: 9.29
Genes affected
GCH1 (HGNC:4193): (GTP cyclohydrolase 1) This gene encodes a member of the GTP cyclohydrolase family. The encoded protein is the first and rate-limiting enzyme in tetrahydrobiopterin (BH4) biosynthesis, catalyzing the conversion of GTP into 7,8-dihydroneopterin triphosphate. BH4 is an essential cofactor required by aromatic amino acid hydroxylases as well as nitric oxide synthases. Mutations in this gene are associated with malignant hyperphenylalaninemia and dopa-responsive dystonia. Several alternatively spliced transcript variants encoding different isoforms have been described; however, not all variants give rise to a functional enzyme. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_pathogenic. Variant got 6 ACMG points.
PM1
In a chain GTP cyclohydrolase 1 (size 249) in uniprot entity GCH1_HUMAN there are 25 pathogenic changes around while only 3 benign (89%) in NM_000161.3
PM2
Very rare variant in population databases, with high coverage;
PP3
MetaRNN computational evidence supports a deleterious effect, 0.864
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
GCH1 | NM_000161.3 | c.662T>C | p.Met221Thr | missense_variant | 6/6 | ENST00000491895.7 | NP_000152.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
GCH1 | ENST00000491895.7 | c.662T>C | p.Met221Thr | missense_variant | 6/6 | 1 | NM_000161.3 | ENSP00000419045.2 |
Frequencies
GnomAD3 genomes AF: 0.0000197 AC: 3AN: 152172Hom.: 0 Cov.: 33
GnomAD3 genomes
AF:
AC:
3
AN:
152172
Hom.:
Cov.:
33
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000161 AC: 4AN: 248966Hom.: 0 AF XY: 0.0000148 AC XY: 2AN XY: 134762
GnomAD3 exomes
AF:
AC:
4
AN:
248966
Hom.:
AF XY:
AC XY:
2
AN XY:
134762
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000438 AC: 64AN: 1461674Hom.: 0 Cov.: 31 AF XY: 0.0000399 AC XY: 29AN XY: 727160
GnomAD4 exome
AF:
AC:
64
AN:
1461674
Hom.:
Cov.:
31
AF XY:
AC XY:
29
AN XY:
727160
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000197 AC: 3AN: 152172Hom.: 0 Cov.: 33 AF XY: 0.0000135 AC XY: 1AN XY: 74334
GnomAD4 genome
AF:
AC:
3
AN:
152172
Hom.:
Cov.:
33
AF XY:
AC XY:
1
AN XY:
74334
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ExAC
AF:
AC:
4
ClinVar
Significance: Conflicting classifications of pathogenicity
Submissions summary: Pathogenic:2Uncertain:5
Revision: criteria provided, conflicting classifications
LINK: link
Submissions by phenotype
not provided Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | Athena Diagnostics | Jan 19, 2024 | Available data are insufficient to determine the clinical significance of the variant at this time. The frequency of this variant in the general population is uninformative in assessment of its pathogenicity. (http://gnomad.broadinstitute.org) This variant has been identified in at least one individual with autosomal recessive dopa-responsive dystonia. Computational tools disagree on the variant's effect on normal protein function. - |
Uncertain significance, criteria provided, single submitter | clinical testing | AiLife Diagnostics, AiLife Diagnostics | Mar 29, 2022 | - - |
Dystonia, dopa-responsive, with or without hyperphenylalaninemia, autosomal recessive Pathogenic:1
Pathogenic, no assertion criteria provided | literature only | OMIM | Jul 01, 1998 | - - |
Intellectual disability Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Diagnostic Laboratory, Strasbourg University Hospital | Sep 10, 2020 | - - |
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Aug 22, 2024 | Variant summary: GCH1 c.662T>C (p.Met221Thr) results in a non-conservative amino acid change located in the GTP cyclohydrolase I domain (IPR020602) of the encoded protein sequence. Three of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 1.6e-05 in 248966 control chromosomes. The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. c.662T>C has been reported in the literature in an individual affected with Dystonia (Furukawa_1998). These data do not allow any conclusion about variant significance. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publication have been ascertained in the context of this evaluation (PMID: 9667588). ClinVar contains an entry for this variant (Variation ID: 9281). Based on the evidence outlined above, the variant was classified as uncertain significance. - |
GTP cyclohydrolase I deficiency;C1851920:Dystonia 5 Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Sep 10, 2022 | This sequence change replaces methionine, which is neutral and non-polar, with threonine, which is neutral and polar, at codon 221 of the GCH1 protein (p.Met221Thr). This variant is present in population databases (rs104894434, gnomAD 0.004%). This missense change has been observed in individual(s) with clinical features of GCH1-related conditions (PMID: 9667588, 30314816). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 9281). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt GCH1 protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Dystonia 5 Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Victorian Clinical Genetics Services, Murdoch Childrens Research Institute | Sep 23, 2024 | Based on the classification scheme VCGS_Germline_v1.3.4, this variant is classified as VUS-3A. Following criteria are met: 0103 - Dominant negative and loss of function are known mechanisms of disease in this gene and are associated with dystonia, DOPA-responsive (MIM#128230) and hyperphenylalaninaemia, BH4-deficient, B (MIM#233910). Missense variants have been proven to have both a loss of function and dominant negative effect on protein function, causing both dominant and recessive forms of dystonia. Only loss of function variants have been reported for hyperphenylalaninaemia (PMID: 11026444,17111153). (I) 0108 - This gene is associated with both recessive and dominant disease (OMIM, PMID: 33713342). (I) 0112 - The dominant dystonia condition associated with this gene has incomplete penetrance (PMID: 11359069). (I) 0115 - Variants in this gene are known to have variable expressivity (PMID: 33713342). (I) 0200 - Variant is predicted to result in a missense amino acid change from methionine to threonine. (I) 0252 - This variant is homozygous. (I) 0304 - Variant is present in gnomAD (v2) <0.01 (5 heterozygotes, 0 homozygotes). (SP) 0502 - Missense variant with conflicting in silico predictions and uninformative conservation. (I) 0600 - Variant is located in the annotated GTP cyclohydrolase I domain (DECIPHER). (I) 0710 - Another missense variant comparable to the one identified in this case has inconclusive previous evidence for pathogenicity. p.(Met221Val) has been submitted to ClinVar once as a VUS. (I) 0808 - Previous reports of pathogenicity for this variant are conflicting. This variant has been submitted to ClinVar once as pathogenic and twice as a VUS. This variant has also been identified once in a heterozygous individual with Parkinson's disease and classified as pathogenic (PMID: 30314816), and in a compound heterozygous state in an individual with severe dystonia and developmental delay (PMID: 9667588, 9566389). (I) 0906 - Segregation evidence for this variant is inconclusive. This variant was observed in an individual with severe dystonia and developmental delay and her unaffected father. This individual was also compound heterozygous for another GCH1 variant which segregated with DOPA-responsive dystonia in three affected members of her family, in whom this variant was not observed. However, the compound heterozygous proband was noted to be more severely affected and with earlier onset of symptoms (PMID: 9667588, 9566389). (I) 1010 - Functional evidence for this variant is inconclusive. Patient lymphoblasts from a compound heterozygous individual had reduced neopterin levels compared to controls. However, lymphoblasts from their father who is heterozygous for just this variant did not have reduced neopterin levels, while lymphoblasts from individuals with only the other variant did have reduced neopterin levels (PMID: 9566389). (I) 1208 - Inheritance information for this variant is not currently available in this individual. (I) Legend: (SP) - Supporting pathogenic, (I) - Information, (SB) - Supporting benign - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Uncertain
DANN
Benign
DEOGEN2
Pathogenic
D;D;D
Eigen
Benign
Eigen_PC
Benign
FATHMM_MKL
Pathogenic
D
LIST_S2
Uncertain
.;D;.
M_CAP
Uncertain
D
MetaRNN
Pathogenic
D;D;D
MetaSVM
Pathogenic
D
MutationAssessor
Benign
N;N;N
PrimateAI
Pathogenic
D
PROVEAN
Benign
.;N;N
REVEL
Uncertain
Sift
Benign
.;T;T
Sift4G
Benign
T;T;T
Polyphen
B;B;B
Vest4
MutPred
Gain of phosphorylation at M221 (P = 0.0357);Gain of phosphorylation at M221 (P = 0.0357);Gain of phosphorylation at M221 (P = 0.0357);
MVP
MPC
1.2
ClinPred
T
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at